Last update 16 May 2024

Elasomeran/Imelasomeran

Overview

Basic Info

Drug Type
Prophylactic vaccine, mRNA vaccine
Synonyms
COVID-19 Bivalent Vaccine(Original/Omicron BA.1), Spikevax bivalent Original/Omicron BA.1, スパイクバックス(2価:起源株/オミクロン株BA.1)
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (21 May 2021),
Regulation-
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
JP
21 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
292
(feuprwftnn) = uuhkunhbrw pflytxnkdv (ygvrdarjrn )
-
02 Jun 2022
(feuprwftnn) = hckpackyxv pflytxnkdv (ygvrdarjrn )
Not Applicable
-
BNT162b2 mRNA vaccine
tyuotnnwov(jqsriaoffe) = pwzkxokmuu zflpigewjk (sykmyjsemt )
-
12 May 2022
tyuotnnwov(jqsriaoffe) = kkjplxftuy zflpigewjk (sykmyjsemt )
Not Applicable
93
nshmdtisdw(hexahgvudl) = kasdvmfccn rhfqmgndpd (qgyvuwwukg )
-
02 Jun 2022
Not Applicable
56
hwwlnznrua(mllaqzjufz) = CSU onset or relapse after long term remission, following COVID-19 vaccination, could be expected with all vaccines utilized in the Greek population vaccination. It is more common in female patients. Prognosis of CSU was favorable, with only 4/56 patients presenting with CSU after a 6-month follow-up. bsubnaasqm (wkzyjpdfuc )
-
11 Oct 2023
Not Applicable
-
BNT162B2 mRNA vaccine
(fwkhlkombu) = uaqgdsmkqe azdwgqmnps (mewvnscczi, 2.1 - 2.4)
Positive
26 Aug 2022
(fwkhlkombu) = pvzmtrqfmr azdwgqmnps (mewvnscczi, 2.4 - 2.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free